Calcipotriene

CHEMBL1200666 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
412.6 g/mol
LogP
4.3
Phase
4

A synthetic analogue of the active form of vitamin D used topically to treat mild to moderate plaque psoriasis. It works by slowing the rapid skin cell growth and normalizing the skin cell lifecycle associated with psoriasis. It is well tolerated on most body areas but should be avoided on the face due to the risk of irritation.

Masse moléculaire

412,6000 g/mol

LogP

4,30

TPSA

60,70 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O

InChI

InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1

Molecular Formula

C27H40O3

HBD / HBA

3 / 3

Liaisons Rotatives

5

Atomes Lourds

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A synthetic analogue of the active form of vitamin D used topically to treat mild to moderate plaque psoriasis. It works by slowing the rapid skin cell growth and normalizing the skin cell lifecycle associated with psoriasis. It is well tolerated on most body areas but should be avoided on the face due to the risk of irritation.

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

Yes, Calcipotriene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200666. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5288783. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.